logo

Glycomimetics, Inc. (GLYC)



Trade GLYC now with
  Date
  Headline
8/5/2021 7:41:47 AM GlycoMimetics Q2 Loss/shr $0.28 Vs. Loss/shr $0.32 Prior Year
7/22/2021 9:14:34 AM GlycoMimetics : Trial Launches To Evaluate Uproleselan Added To Cladribine Plus Low-Dose Cytarabine In AML Patients
7/12/2021 9:08:11 AM GlycoMimetics Initiates Clinical Trial Evaluating Uproleselan In Combination With Venetoclax And Azacitidine
5/26/2021 9:52:18 AM GLYC: First Patient Dosed In Trial Evaluating Uproleselan As Prophylactic Agent To Reduce Gastrointestinal Toxicities
5/3/2021 7:52:01 AM GlycoMimetic Q1 Loss Per Share $0.28 Vs Loss $0.18 Last Year
3/4/2021 8:40:53 AM Apollomics Doses First Patient In Phase 1 Clinical Trial In China Of GlycoMimetics' Uproleselan For Treatment Of AML
11/6/2020 7:40:09 AM GlycoMimetics Q3 Loss Per Share $0.29 Vs Loss $0.31 Last Year
10/26/2020 9:04:54 AM GlycoMimetics Announces That New Post Hoc Analyses Of The Phase 3 RESET Study
4/7/2020 9:18:07 AM GlycoMimetics Appoints Myra Rosario Herrle As VP, Regulatory Affairs
2/28/2020 8:10:39 AM GlycoMimetics Q4 Loss/shr Widens To $0.34 From $0.32 Prior Year
2/4/2020 9:57:20 AM GlycoMimetics Announces Several Achievements For Its GMI-1359 Development Program
1/6/2020 9:09:03 AM GlycoMimetics And Apollomics To Develop And Commercialize Uproleselan And GMI-1687 In China
3/1/2016 9:54:46 AM Canaccord Is Raising GlycoMimetics, Inc. (GLYC) 2016 Estimate To -1.92 From -2.27